Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

NCT01582204 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Renal Cancer

Interventions

DRUG: 124IcG250

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]